Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TScan Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding TScan Therapeutics, Inc.’s stock price such as:

• TScan Therapeutics, Inc.’s current stock price and volume
• Why TScan Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TCRX from analysts
• TCRX’s stock price momentum as measured by its relative strength

About TScan Therapeutics, Inc. (TCRX)

Before we jump into TScan Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Want to learn more about TScan Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TScan Therapeutics, Inc..

What Caused TScan Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 29, 2026, there was 1 analyst who downgraded TScan Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate TScan Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TScan Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

TScan Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TScan Therapeutics, Inc. (TCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of TScan Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 29, 2026, TScan Therapeutics, Inc. has a weighted four-quarter relative price strength of -9.78%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how TScan Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TScan Therapeutics, Inc. Stock Price: Bottom Line

As of June 1, 2026, TScan Therapeutics, Inc.’s stock price is $1.020, which is down 5.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TScan Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.